Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with severe renal impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL) Source: International Congress 2017 – Management of COPD Year: 2017
The absolute bioavailability of fluticasone furoate (FF) and vilanterol (VI) trifenatate following inhaled administration in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with hepatic impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
LATE-BREAKING ABSTRACT: TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
LATE-BREAKING ABSTRACT: TRILOGY: a phase III study to evaluate the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) in COPD patients Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Evaluating lung function response to umeclidinium/vilanterol (UMEC/VI) 62.5/25mcg, UMEC 62.5mcg and VI 25mcg in COPD patients Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
Pharmacokinetics (PK) of mometasone furoate and indacaterol in Japanese and Caucasian healthy subjects after once daily inhalation of QMF149 Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013